Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.…
Theriva Biologics: Q3 Earnings Snapshot
Theriva Biologics (NYSEAMERICAN: TOVX) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 15 employees.
The shares were at 0.1200 USD on 20 November 2026, down 55.6% over 52 weeks. Its 52-week range is 0.1200 USD to 0.4900 USD, and it trades at the bottom of that range.
Its market capitalisation is 5.51M USD.
Theriva Biologics reports return on equity of -154.3%.
It holds more cash than debt, a net cash position of 5.05M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.